Prospective study demonstrates efficacy in improving symptoms and meibomian gland function in dry eye disease, indicating a safe treatment option.
A single Tearmaestro® liquid pulsation treatment significantly improves the primary outcome of patient-reported symptoms at 1 month, with concurrent benefits in tear film stability and meibomian gland function lasting up to 3 months. The treatment demonstrated a favorable safety profile, offering an efficient clinical option for MGD-related dry eye.
No takes yet. Share an insight, caveat, or question.
Yue et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: